A Feasibility Study in Combat Athletes with Mild Traumatic Brain Injury
Launched by MICHAEL HARL · Mar 24, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- • Patients meeting the inclusion criteria will be based on the type of associated suspension; 30-day suspension (head injury without technical knockout or incapacitation), 60-day suspension (head injury with technical knockout or incapacitation), 90-day suspension (head injury with loss of consciousness). These suspension groups are not based on GCS; therefore, GCS is not part of the inclusion criteria. The suspension group injury severity would not include moderate to severe GCS \<13. This group will be divided into randomized groups, patients who will be treated with HBOT and patients who will receive the standard of care, which is rest.
About Michael Harl
Michael Harl is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a robust background in clinical development and regulatory compliance, Mr. Harl oversees a diverse portfolio of clinical trials across various therapeutic areas. His focus on innovation and collaboration fosters strong partnerships with research institutions and healthcare professionals, ensuring the highest standards of quality and integrity in trial execution. Through his leadership, Michael Harl aims to contribute to the development of safe and effective treatments that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Marshfield, Wisconsin, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
